ADPT240517P7500
- 4.80
- 0.000.00%
Adaptive Biotechnologies Newsroom
Market Participants Recognise Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Revenues Pushing Shares 50% Higher
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) shareholders are no doubt pleased to see that the share price has bounced 50% in the last month, although it is still struggling to make up recently
Analysts Offer Insights on Healthcare Companies: Rani Therapeutics Holdings (RANI), Warby Parker (WRBY) and Adaptive Biotechnologies (ADPT)
Why Adaptive Biotechnologies Topped the Market Today
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q1 2024 Earnings Call Transcript
Earnings Call Summary | Adaptive Biotechnologies(ADPT.US) Q1 2024 Earnings Conference
The following is a summary of the Adaptive Biotechnologies Corporation (ADPT) Q1 2024 Earnings Call Transcript:Financial Performance:Adaptive Biotechnologies reported Q1 2024 revenue of $41.99 million
Express News | Adaptive Biotechnologies Corp : Btig Raises Target Price to $6 From $5
Analysts Offer Insights on Healthcare Companies: Adaptive Biotechnologies (ADPT), Veracyte (VCYT) and Nevro Corp (NVRO)
Analysts Offer Insights on Healthcare Companies: Clover Health Investments (CLOV), Cogent Biosciences (COGT) and Adaptive Biotechnologies (ADPT)
Adaptive Biotechnologies Corp (ADPT) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
Compared to Estimates, Adaptive Biotechnologies (ADPT) Q1 Earnings: A Look at Key Metrics
Adaptive Biotechnologies Q1 Loss Decreases, Beats Estimates
Adaptive Biotechnologies | 10-Q: Quarterly report
Earnings Flash (ADPT) ADAPTIVE BIOTECHNOLOGIES Reports Q1 Revenue $41.9M, Vs. Street Est of $38.8M
04:36 PM EDT, 05/07/2024 (MT Newswires) -- Earnings Flash (ADPT) ADAPTIVE BIOTECHNOLOGIES Reports Q1 Revenue $41.9M, vs. Street Est of $38.8M
Express News | Adaptive Biotechnologies Corp: Expect Full Year Total Company Operating Expenses, Including Cost of Revenue, to Be Between $350 Mln and $360 Mln
Express News | Adaptive Biotechnologies Corp: Expects Full Year Revenue for Mrd Business to Be Between $135 Mln and $140 Mln
Express News | Adaptive Biotechnologies Corp: Cash, Cash Equivalents and Marketable Securities Was $308.9 Mln as of March 31, 2024
Express News | Adaptive Biotechnologies Q1 Revenue USD 41.873 Million Vs. Ibes Estimate USD 38.8 Million
Express News | Adaptive Biotechnologies Q1 Operating Expenses USD 90.635 Million
Express News | Adaptive Biotechnologies Q1 Adjusted Ebitda USD -28.2 Million Vs. Ibes Estimate USD -32.9 Million
Express News | Adaptive Biotechnologies Q1 EPS USD -0.33